Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice
Leslie Jacobson, … , Gillian Morriss-Kay, Angela Vincent
Leslie Jacobson, … , Gillian Morriss-Kay, Angela Vincent
Published April 1, 1999
Citation Information: J Clin Invest. 1999;103(7):1031-1038. https://doi.org/10.1172/JCI5943.
View: Text | PDF
Article

Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice

  • Text
  • PDF
Abstract

Arthrogryposis multiplex congenita (AMC) is characterized by fixed joint contractures and other deformities, sometimes resulting in fetal death. The cause is unknown in most cases, but some women with fetuses affected by severe AMC have serum antibodies that inhibit fetal acetylcholine receptor (AChR) function, and antibodies to fetal antigens might play a pathogenic role in other congenital disorders. To investigate this possibility, we have established a model by injecting pregnant mice with plasma from four anti-AChR antibody–positive women whose fetuses had severe AMC. We found that human antibodies can be transferred efficiently to the mouse fetus during the last few days of fetal life. Many of the fetuses of dams injected with AMC maternal plasmas or Ig were stillborn and showed fixed joints and other deformities. Moreover, similar changes were found in mice after injection of a serum from one anti-AChR antibody–negative mother who had had four AMC fetuses. Thus, we have confirmed the role of maternal antibodies in cases of AMC associated with maternal anti-AChR, and we have demonstrated the existence of pathogenic maternal factors in one other case. Importantly, this approach can be used to look at the effects of other maternal human antibodies on development of the fetus.

Authors

Leslie Jacobson, Agata Polizzi, Gillian Morriss-Kay, Angela Vincent

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Transfer of human anti-acetylcholine receptor (anti-AChR) antibodies fro...
Transfer of human anti-acetylcholine receptor (anti-AChR) antibodies from dam to fetus. (a) Pregnant dams were injected daily with 0.5 ml of plasma from a typical, nongravid, patient with myasthenia gravis (MG), containing 90 nmol/l of anti-AChR. At different time points, anti-AChR antibody was measured in 1 μl of the dams’ sera and 25 μl of extracts of their fetuses. Subsequent analysis showed that 25 μl of fetal extracts (from 12.5 μl of fetal tissue) was equivalent to 3.5 μl of fetal serum. Thus, at E18, the fetal serum would have contained about 8 fmol/μl of anti-AChR. Similar results were obtained in two other experiments, and raised anti-AChR levels were also detected in the fetal yolk sacs. (b) Anti-AChR antibodies measured in sera and fetal extracts taken at E18/19 from dams injected from E9 to E16 with AMC-M plasmas.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts